Navigation Links
AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Date:3/11/2009

hase 2 trial in advanced ovarian and endometrial cancers. - December - Sale of AEterna Zentaris rights to royalties on future sales of Cetrotide(R), covered by the Company's license agreement with Merck Serono, to Cowen Healthcare Royalty Partners L.P. ("Cowen") for gross consideration of $52.5 million. - Completion of patient recruitment for the safety trial of the Phase 3 program in BPH with cetrorelix. - Appointment of Matthias Seeber, MBA, as Company Senior Vice President, Administration and Legal Affairs. - Subsequent to year end - The Company entered into a development, commercialization and license agreement with sanofi-aventis for the development, registration and marketing of cetrorelix in BPH for the United States market. The agreement includes an initial upfront payment of $30 million and up to $135 million in additional payments upon achieving certain pre-established regulatory and commercial milestones, as well as escalating double-digit royalties on future net sales of cetrorelix for BPH in the United States.

Juergen Engel, Ph. D., AEterna Zentaris' President and Chief Executive Officer commented, "I am proud of our achievements of the past 12 months. At the financial level, we generated nearly $100 million in 2008 and in the first few months of 2009, through multiple non-dilutive transactions and a major pharmaceutical partnership with sanofi-aventis for our lead compound, cetrorelix. At the drug development level, we completed the recruitment of over 1,600 patients for our Phase 3 program in BPH with cetrorelix, according to schedule. We now look forward to disclosing results of this program throughout the second half of 2009. We also made significant progress with our lead oncology compound, AEZS-108, in endometrial and ovarian cancer with results expected by the end of this ye
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 Shimadzu ... chromatography systems, Prominence-i and Nexera-i, adding to the ... Combining excellent functionality, an intuitive operating environment, and ... a more efficient workflow for conventional to ultra-high-speed ... innovative, intuitive and intelligent design so users can ...
(Date:8/19/2014)... -- Research and Markets  has announced the addition of ... Business Report" report to their offering. ... Cells (SOFCs) in US$ Thousands. The report provides separate comprehensive ... Europe , Asia-Pacific , and ... the period 2012 through 2020. Market data and analytics are ...
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the ... industry, recently announced the formation of the company,s Medical ... announce the addition of Dr. William E. Gannon, ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with ... variety of therapeutic areas and set strategic goals for ...
(Date:8/19/2014)... Sales Horizons, a leader in sales ... sales skills training course to help companies develop ... staff spend the majority of their time on client ... or physician practice – providing support and education to ... Sales Horizons believes clinical staff are and should be ...
Breaking Biology Technology:Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3
... speculate that the Greater Madison area, while a key ... the "critical mass" of talent, innovation, and specialization necessary ... sustained growth. , ,But as area biotech leaders and ... discovery tool provider, Caden Biosciences , to a ...
... Madison, Wis. - The Madison-based Imago Scientific ... to Iowa State University's College of Engineering ... High Throughput Atom-Scale Analysis. , ,The lab will be ... Discovery, which is led by Balaji Narasimhan, an associate ...
... to the future growth and success of the state ... state boasts significant competitive advantages in terms of talent, ... mass needed to compete with our most significant competition ... resources so vital to building and sustaining economic growth. ...
Cached Biology Technology:Caden Biosciences may signal critical mass 2Regional collaboration is key to state's future 2Regional collaboration is key to state's future 3
(Date:8/20/2014)... approximately 3 million infants, a team of scientists across ... Massachusetts Medical School, have shown that newborn screening for ... public health newborn screening programs. Data from 11 newborn ... the Journal of the American Medical Association ... newborns is higher than previously thought and believed to ...
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... U.S. Department of Energy this month awarded a group ... develop bacteria that can turn the methane in natural ... we,re shooting for will have the same fuel characteristics ... professor of chemical engineering and microbiology. "It can be ...
... Innes Centre will publish the first RNA sequence data on the ... will release the data via a website to a system designed ... used to crowdsource expertise during the 2011 E. coli ... able to access the RNA sequence and start to analyse it ...
... University of Illinois at Urbana-Champaign has received a fiveyear, $5.7 ... in corn. These strains have the potential to combat the ... yield. A team at the Institute for Genomic Biology in ... lead the research. "Ozone can cause major damage ...
Cached Biology News:Energy Deptartment funds UW project to turn wasted natural gas into diesel 2Crowdsourcing to kickstart comeback from ash dieback 2University of Illinois receives grant to study ozone resistance in corn 2
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
...
Biology Products: